Drug companies should keep a goal of effective communications as the priority in medical publications
The case for a single enterprise-wide learning management system
"If we had asked them, they would have asked for faster horses." ~ Henry Ford
More personal control over healthcare and the desire for more access to information drive consumer attitudes
GSK invests in online resources to address ‘the whole patient’
Recent regulatory actions and court cases highlight the importance of due diligence in reporting the value of service fees when federal reimbursements are concerned. The financial consequences can be substantial
True 'market access' should involve coordinated approaches to patients and their healthcare providers
The growing complexity of managed-markets contract support makes outsourcing a near-necessity for Small Pharma, and a better option for Big Pharma
Recent product contamination incidents are highlighting the importance of having reliably clean pallets for warehousing and shipping
Exparel was initially approved in 2011 for single-dose infiltration into a surgical site.
Technology is enabling more resources to reach the medical affairs teams—in a compliant manner
Good design of vaults and cages for DEA-regulated materials calls for meeting regulatory requirements while accommodating operational practices
How drugmakers can navigate the program’s pricing challenges and regulatory developments.
Taking a market-by-market approach to maximizing value after loss of exclusivity
European experience to date indicates a changing perspective on biosimilar pricing
As the number of specific services associated with sample distribution has grown, so has the number of service providers a manufacturer might use. It’s time to think about consolidating these services
The recent acquisition of US Oncology by McKesson highlights the rising importance of the distributor-led networks
Promotional content produced for, or derived from, digital media presents its own management and compliance complexities
True 'market access' should involve coordinated approaches to patients and their healthcare providers
The biologics development and approval process for pharmaceutical companies around the world is typically long and complex, which increases the risk of inaccurately forecasting demand
Class-wide opioid REMS will affect four million patients and require cooperation of more than 25 drug manufacturers
Well designed quality systems follow the product life cycle and foster a culture of quality
Evidence Generation Is the Foundation to Optimal Product Positioning
HDMA seeks to encourage more outreach to business partners and government
A look into the growing compliance risks associated with patient services
New technological capabilities will enable management of sample-distribution processes to keep up with a challenging environment
Addressing patient recruitment and retention issues is a natural role for CTEs